Aparna Lakshmi, I. published the artcileHistone deacetylase inhibitors in cancer therapy: an update, Product Details of C10H18O4, the publication is International Journal of Pharmaceutical Sciences Review and Research (2011), 10(1), 38-44, database is CAplus.
A review. Histone deacetylase inhibitors (HDACi) are novel class of anti-neoplastic agents and they mostly act by enhancing acetylation of histones, and promotes uncoiling of chromatin and activation of a large number of genes implicated in the regulation of cell survival like proliferation, differentiation and apoptosis. Most of them are therapeutic targets for cancer, neurodegenerative diseases and a number of other disorders. The histone deacetylases (HDACs) can be divided into two families, which include a total of eleven enzymes. The Zn+2 dependent HDAC family composed of class I (HDACs 1, 2, 3 and 8), class II a/b (HDACs 4, 5, 6, 7, 9 and 10), and class IV (HDAC 11) and (2) Zn+2 independent NAD-dependent class III SIRT enzymes. Histone deacetylase inhibitors (HDACi) which are been investigated for their antitumor potency are of with different chem. structures i.e Short-chain fatty acids (e.g. sodium butyrare), phenylburyrare, valproic acid and (AN-9), Hydroxyaminic acids (SAHA, pyroxamide, TSA, oxamflarin and CHPAs), Synthetic benzamide derivatives (e.g., MS-275 and Cl-994), Cyclic tetrapeptides (such as depsipeptide, trapoxin and apicidin), Electrophilic ketones (trifluoromethylketone), and Miscellaneous (depudecin, SNDX-275 and isothiocyanates). HDACi can have multiple mechanisms of inducing transformed cell growth arrest and cell death. These HDAC substrates are directly or indirectly involved in numerous important cell pathways including control of gene expression, regulation of cell proliferation, differentiation, migration, and death. As a consequence, HDACi can have multiple mechanisms of inducing transformed cell growth arrest and cell death. HDACi can be used in combination with radiation therapy, antitubulin agents, topoisomerase I and II inhibitors etc.
International Journal of Pharmaceutical Sciences Review and Research published new progress about 122110-53-6. 122110-53-6 belongs to esters-buliding-blocks, auxiliary class Aliphatic hydrocarbon chain,Ester,Inhibitor, name is (Pivaloyloxy)methyl butyrate, and the molecular formula is C10H18O4, Product Details of C10H18O4.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics